Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with moderate-to-severe asthma, dimming hopes it could help offset the patent expiry of its ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Maryland lawmakers have expanded a state board’s authority to set statewide upper-payment limits on high-cost prescriptions.

With broadcasts of the college football and NFL playoffs, as well as the men’s and women’s college basketball tournaments, many drugmakers looked to sports for advertising opportunities in Q1.

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Lichenification occurs when repeated scratching or rubbing causes skin to thicken and become leathery. Certain skincare and ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...